Dr. Huang obtained his BS in Biological Science and PhD in Bioinformatics from Peking University. During his PhD studies, under the guidance of Dr. Liping Wei, he developed MosaicHunter, the first computational tool capable of systematically identifying somatic single-nucleotide variants from non-cancer whole-genome and exome sequencing data.

Dr. Huang then received his postdoctoral training with Drs. Christopher Walsh, Alice Lee, and Matthew Warman at Boston Children's Hospital and Harvard Medical School, where he pioneered in revealing the accumulation of somatic mutations in various tissue types and their contribution to many diseases including Alzheimer's disease, autism, and arteriovenous malformation.

In 2023, Dr. Huang opened his independent laboratory in the Division of Genetics and Genomics at Boston Children's Hospital, with a focus on utilizing computational genomic approaches to investigate the characteristics of somatic mutations in development and aging and their impact on human health. His research projects are funded by NIH/NIA, NIH/NHLBI, Alzheimer's Association, and Boston Children’s Hospital​. 

Yingxi joined the lab in 2024 after her PhD and postdoctoral training in computational biology under the supervision of Professor Jiguang Wang at Hong Kong University of Science and Technology. Through interdisciplinary collaborations with brain vascular biologists and clinicians, her work has unveiled novel genomic and immune biomarkers in brain vascular malformations and generated new insights into precision medicine in glioma and colorectal cancer. She is interested in developing and tailoring computational methods to study the role of somatic mutation in neurogenetics and translate the discoveries into new therapies.

Mengyue joined the lab in 2025 after her PhD training in statistical genetics and computational biology under the supervision of Professor Jian Yang at Westlake University and Zhejiang University. By utilizing somatic mutations as molecular fossils, she developed a novel framework called dNdS-Fun to decipher the selection processes of somatic mutations in cancer development, leading to the identification of numerous selected genes and elements during tumor evolution, including many novel noncoding elements. She is interested in developing and applying innovative computational methods to study the role of somatic mutations in other age-related diseases, such as Alzheimer's disease. Through investigating their dynamic accumulation and pathogenic mechanisms, she aims to uncover the role and significance of somatic mutations in aging and age-related diseases.

Yun joined the lab in 2025 and is co-mentored by Dr. Michael Miller at Brigham and Women’s Hospital. He completed his PhD at Boston University under the supervision of Dr. Ana Fiszbein, where he studied the interplay between mRNA transcription and the splicing machinery. He received his MS and BS in Bioengineering from Hanyang University in South Korea, where he worked on developing gene delivery carriers targeting brain tumors and ischemic stroke under the supervision of Dr. Minhyung Lee. Yun is broadly interested in how somatic mutations pathologically alter the transcriptomic landscape of the aging brain and contribute to neurodegenerative disease.

Isabella joined the lab in 2026 and is co-mentored by Dr. Sattar Khoshkhoo at Brigham and Women’s Hospital. She completed her PhD in Neuroscience under the supervision of Dr. Diogo Veiga and Dr. Iscia Lopes-Cendes at Universidade Estadual de Campinas in Brazil. Her doctoral research focused on the cellular characterization of epileptogenic cortical malformations and pediatric neurodevelopment through integration of single-cell epigenomic and transcriptomic data, leading to the creation of cellular atlases and novel diagnostic markers. She earned her BSc in biological sciences, where she applied machine-learning approaches and conducted functional studies of the zebrafish brain. Isabella is interested in understanding the role of somatic variants in epilepsy-related conditions, with the goal of contributing to the development of improved diagnostic and therapeutic strategies.

Weiwei joined the lab in 2026 and is co-mentored by Dr. Sangita Choudhury. Her interdisciplinary training spans computational mathematics, biostatistics, and bioinformatics. She received her PhD from Karolinska Institutet under the primary supervision of Prof. Zongli Zheng, where she focused on methodological and algorithm development, including ultrasensitive fusion detection from FFPE samples and sensitive mutation detection from ctDNA. During her previous postdoctoral work at Dana-Farber Cancer Institute, Weiwei focused on translational cancer research and multi-omics data analysis, developing bioinformatics pipelines across multiple cloud platforms and applying machine learning and deep learning approaches to computational genomics, including genomics foundation models. She is interested in developing computational and bioinformatics methods to study somatic mutations in cardiovascular and cerebrovascular diseases and aging, and in leveraging statistical learning and AI approaches to better understand their biological and clinical significance.

Chao joined the lab in 2026 and is co-mentored by Dr. Sattar Khoshkhoo at Brigham and Women’s Hospital. She completed her PhD under the supervision of Dr. Ping Zhu at Peking Union Medical College, where she used single-cell multi-omics approaches to study the epigenetic regulation and functional heterogeneity of hematopoietic stem and progenitor cells during lineage differentiation. Her current research focuses on developing computational approaches to characterize somatic mutations in neural systems and investigate their functional roles in neurological diseases, such as epilepsy, with an interest in their clinical relevance.

Irene is an MD-PhD candidate in the Harvard/MIT MD-PhD Program, with her MD through the HST track. She joined the lab in 2023 and is co-mentored by Dr. Christopher Walsh. She obtained her BA in Neuroscience at Washington University in St. Louis and is pursuing her PhD in the Program in Neuroscience at Harvard Medical School. For her PhD research, she is interested in studying early neurodevelopment and how genetic and epigenetic perturbations interact to cause different medical conditions. 

Yujie Wang is a master’s student in Biomedical Informatics at Harvard Medical School. He joined the lab in 2025 to conduct research and complete his thesis project. He received his B.A. in Mathematics from Vanderbilt University. He is broadly interested in computational genomics, with a focus on developing and applying methods to study somatic mutations in human development, aging, and neurodegenerative disorders. These interests build on his prior research benchmarking small-variant callers across both long- and short-read sequencing data.